SCHEMBL24253349

SCHEMBL24253349

CC(C)Cc1nc2c(s1)CN(C)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.45
RAD52 P43351 1/20 0.41
RECQL P46063 1/20 0.41
OGA O60502 1/20 0.39
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 3/20 0.37
GAA P10253 2/20 0.37
F10 P00742 1/20 0.37
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
EPHA2 P29317 1/20 0.35
KDR P35968 1/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312993 0.82 GRM5 (0.48) GRM5RAD52RECQLOGAKDM4E
SCHEMBL29086185 0.81 GRM5 (0.47) GRM5RAD52RECQLOGAKDM4E
SCHEMBL30620417 0.81 GRM5 (0.47) GRM5RAD52RECQLOGAKDM4E
SCHEMBL1106412 0.79 GRM5 (0.48) GRM5RAD52RECQLOGAKDM4E
SCHEMBL29086322 0.77 GRM5 (0.41) GRM5RAD52RECQLOGAKDM4E
SCHEMBL15293639 0.75 PDK1 (0.44) KDM4EALDH1A1SMN1; SMN2HPGDGAA
SCHEMBL12356882 0.75 PDK1 (0.44) GRM5SMN1; SMN2GAAMEN1MAPT
SCHEMBL29011049 0.74 GRM5 (0.44) GRM5RAD52RECQLKDM4EALDH1A1
SCHEMBL209848 0.73 GRM5 (0.51) GRM5RAD52RECQLOGAKDM4E
SCHEMBL8051769 0.73 GRM5 (0.51) GRM5RAD52RECQLOGAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GRM5 3607/4885RAD52 1394/4885RECQL 361/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 GRM5 3607/4885RAD52 1394/4885RECQL 361/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GRM5 3607/4885RAD52 1394/4885RECQL 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.